194 related articles for article (PubMed ID: 30389778)
21. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
22. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
23. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
[TBL] [Abstract][Full Text] [Related]
25. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
26. Lessons learned after 20 years of real-world experience with natalizumab.
Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
[TBL] [Abstract][Full Text] [Related]
27. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
28. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
29. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
[TBL] [Abstract][Full Text] [Related]
30. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
Kleiter I; Schröder M; Lürding R; Schuierer G; Clifford DB; Bogdahn U; Steinbrecher A; Pöschl P
Mult Scler; 2010 Jun; 16(6):749-53. PubMed ID: 20453014
[TBL] [Abstract][Full Text] [Related]
31. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
[TBL] [Abstract][Full Text] [Related]
32. A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study.
Ishii J; Shishido-Hara Y; Kawamoto M; Fujiwara S; Imai Y; Nakamichi K; Kohara N
Intern Med; 2018 Sep; 57(18):2727-2734. PubMed ID: 29709947
[TBL] [Abstract][Full Text] [Related]
33. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
[TBL] [Abstract][Full Text] [Related]
35. Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance.
Wijburg MT; Warnke C; Killestein J; Wattjes MP
J Neurol; 2020 Sep; 267(9):2599-2602. PubMed ID: 32385682
[TBL] [Abstract][Full Text] [Related]
36. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
Enzinger C
Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038
[No Abstract] [Full Text] [Related]
37. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
[TBL] [Abstract][Full Text] [Related]
39. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
Scarpazza C; Signori A; Cosottini M; Sormani MP; Gerevini S; Capra R
Mult Scler; 2020 Sep; 26(10):1227-1236. PubMed ID: 31144589
[TBL] [Abstract][Full Text] [Related]
40. Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report.
De Masi R; Orlando S; Armenise S; Spagnolo P; Capra R; Costa MC
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
